rs191746041
Positions:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001130987.2(DYSF):c.3756+9G>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000506 in 1,610,478 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00081 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00047 ( 0 hom. )
Consequence
DYSF
NM_001130987.2 intron
NM_001130987.2 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.717
Genes affected
DYSF (HGNC:3097): (dysferlin) The protein encoded by this gene belongs to the ferlin family and is a skeletal muscle protein found associated with the sarcolemma. It is involved in muscle contraction and contains C2 domains that play a role in calcium-mediated membrane fusion events, suggesting that it may be involved in membrane regeneration and repair. In addition, the protein encoded by this gene binds caveolin-3, a skeletal muscle membrane protein which is important in the formation of caveolae. Specific mutations in this gene have been shown to cause autosomal recessive limb girdle muscular dystrophy type 2B (LGMD2B) as well as Miyoshi myopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.78).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DYSF | NM_001130987.2 | c.3756+9G>T | intron_variant | ENST00000410020.8 | NP_001124459.1 | |||
DYSF | NM_003494.4 | c.3702+9G>T | intron_variant | ENST00000258104.8 | NP_003485.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DYSF | ENST00000258104.8 | c.3702+9G>T | intron_variant | 1 | NM_003494.4 | ENSP00000258104 | A1 | |||
DYSF | ENST00000410020.8 | c.3756+9G>T | intron_variant | 1 | NM_001130987.2 | ENSP00000386881 | A1 |
Frequencies
GnomAD3 genomes AF: 0.000808 AC: 123AN: 152196Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
123
AN:
152196
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000590 AC: 145AN: 245920Hom.: 0 AF XY: 0.000600 AC XY: 80AN XY: 133440
GnomAD3 exomes
AF:
AC:
145
AN:
245920
Hom.:
AF XY:
AC XY:
80
AN XY:
133440
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000475 AC: 692AN: 1458164Hom.: 0 Cov.: 32 AF XY: 0.000489 AC XY: 355AN XY: 725458
GnomAD4 exome
AF:
AC:
692
AN:
1458164
Hom.:
Cov.:
32
AF XY:
AC XY:
355
AN XY:
725458
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000808 AC: 123AN: 152314Hom.: 0 Cov.: 33 AF XY: 0.000900 AC XY: 67AN XY: 74478
GnomAD4 genome
AF:
AC:
123
AN:
152314
Hom.:
Cov.:
33
AF XY:
AC XY:
67
AN XY:
74478
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:4Benign:5
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not specified Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 05, 2014 | Variant classified as Uncertain Significance - Favor Benign. - |
Likely benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 27, 2015 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | May 26, 2015 | - - |
not provided Benign:3
Likely benign, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Apr 13, 2018 | This variant is associated with the following publications: (PMID: 23519732, 27884173) - |
Qualitative or quantitative defects of dysferlin Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Nov 15, 2018 | The DYSF c.3702+9G>T variant has been reported in one study and in one patient in a compound heterozygous state with a missense variant (Nilsson et al. 2013). Control data are not available for this variant, which is reported at a frequency of 0.01327 in the Mandinka in Gambia population of the 1000 Genomes Project. Functional studies using immunohistochemical staining of quadriceps muscle from the patient showed an absence of membrane-bound dysferlin secondary to the intracellular aggregation of the variant protein. Quantitative RT-PCR and Western blotting showed that intracellular total mRNA and protein levels were increased two- to three-fold respectively compared to healthy controls. Human splicing finder predicts the variant to be deleterious and to destroy a donor splice site in intron 33 likely causing an excision of the coding region required for domain C2D of the protein (exon 33) (Nilsson et al. 2013). Based on the evidence, the c.3702+9G>T variant is classified as a variant of unknown significance but suspicioud for pathogenicity for dysferlinopathy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
DYSF-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 24, 2024 | The DYSF c.3702+9G>T variant is predicted to interfere with splicing. This variant has been reported in the heterozygous state in an individual with Miyoshi myopathy (Table 2, Nilsson et al. 2013. PubMed ID: 23519732). This variant is reported in 0.13% of alleles in individuals of Latino descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at